Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Pramlintide (Symlin)
An educational, source-based comparison of Cagrilintide and Pramlintide (Symlin) — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
Synthetic analog of the pancreatic hormone amylin. Slows gastric emptying, suppresses inappropriate postprandial glucagon, and increases satiety as adjunct to insulin.
- Type 1 diabetes (with insulin)
- Type 2 diabetes on insulin
- • FDA-approved.
- • Boxed warning: severe insulin-induced hypoglycemia.
Cagrilintide vs Pramlintide (Symlin) — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Pramlintide (Symlin) is Amylin Analog · Metabolic.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Pramlintide (Symlin) — type 1 diabetes (with insulin).
- Tag: Weight loss vs FDA-Approved · Metabolic.